Impact of Response in Patients (Pts) With Stem Cell Transplant (SCT)-Ineligible Newly Diagnosed Multiple Myeloma (NDMM) Treated With Continuous Lenalidomide + Low-Dose Dexamethasone (Rd) in the FIRST Trial

Nizar J. Bahlis, Alessandro Corso, Lars‐Olof Mügge, Zhixiang Shen, P. Desjardins, A.-m. Stoppa, O. Decaux, Thierry de Revel, Miquel Granell, Gérald Marit, Hareth Nahi, H Demuynck, Shang‐Yi Huang, Supratik Basu, Annette Ervin‐Haynes, Nicolas Leupin, J Marek, G. Chen, Thierry FaçonClinical 2015 · DOI

BibTeX
@inproceedings{bahlis2015impact,
  author = {Nizar J. Bahlis and Alessandro Corso and Lars‐Olof Mügge and Zhixiang Shen and P. Desjardins and A.-M. Stoppa and O. Decaux and Thierry de Revel and Miquel Granell and Gérald Marit and Hareth Nahi and H Demuynck and Shang‐Yi Huang and Supratik Basu and Annette Ervin‐Haynes and Nicolas Leupin and J Marek and G. Chen and Thierry Façon},
  title = {{Impact of Response in Patients (Pts) With Stem Cell Transplant (SCT)-Ineligible Newly Diagnosed Multiple Myeloma (NDMM) Treated With Continuous Lenalidomide + Low-Dose Dexamethasone (Rd) in the FIRST Trial}},
  booktitle = {Clinical},
  year = {2015},
  doi = {10.1016/j.clml.2015.07.196},
}

Loading related content...

Figure